Generic drug maker Juno can’t withdraw admission ahead of trial over Velcade patent

Article 2019-04-24 1:32 pm By Christine Caulfield | Melbourne

Please login to bookmark

A judge has refused an application by generic drug maker Juno Pharmacueticals to withdraw an admission in a battle with Millennium Pharmaceuticals over its cheap version of breakthrough cancer drug Velcade, denying Juno a potential defence to allegations of patent infringement.

Subscribe to Lawyerly to access this article.

Already a subscriber?
Lost your password?

For information on rights and reprints, contact subscriptions@lawyerly.com.au